Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–260 of 260 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RSV Respiratory Syncytial Virus Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI

NCT06229444
View directory record Official record
Conditions
Influenza, Influenza A, Influenza B, COVID-19, Respiratory Syncytial Virus (RSV)
Interventions
ILI Predictive Alerts, Reactive Content, and Proactive Content, ILI Predictive Alerts, Reactive Content, Proactive Content, No Intervention
Behavioral
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years and older
Enrollment
17,043 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers

NCT01489306
View directory record Official record
Conditions
Drug Safety
Interventions
MDT-637
Drug
Lead sponsor
MicroDose Therapeutx, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

NCT00121108
View directory record Official record
Conditions
Healthy
Interventions
Motavizumab, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
0 Months to 6 Months
Enrollment
2,127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
12
States / cities
Chinle, Arizona • Cibecue, Arizona • Fort Definace, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults

NCT03529773
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Formulation A, Formulation B, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
40
States / cities
Mobile, Alabama • Anaheim, California • La Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

NCT05070546
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection Prevention
Interventions
Ad26.RSV.preF-based Vaccine, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
7
States / cities
Coral Gables, Florida • Miami, Florida • El Dorado, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

NCT06060457
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345, Fluzone HD
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
65 Years and older
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
34
States / cities
Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 15, 2026, 4:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.

NCT04748445
View directory record Official record
Conditions
Healthy
Interventions
SARS-CoV-2/Influenza/RSV RT-PCR
Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
9,151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above

NCT05059301
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
770 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
Waterbury, Connecticut • Brooksville, Florida • Immokalee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age

NCT05903183
View directory record Official record
Conditions
Healthy
Interventions
IVX-A12, Placebo
Biological
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
10
States / cities
Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 15, 2026, 4:22 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Transplacental Transmission of RSV (TTRSV)

NCT05443607
View directory record Official record
Conditions
SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV), Bronchiolitis, Asthma
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
2
States / cities
Metairie, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

NCT03755778
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Itraconazole, Rifampin, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 15, 2026, 4:22 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Safety of RSV Preventive Monoclonal Antibody

NCT07158814
View directory record Official record
Conditions
Fever, Adverse Event Following Immunisation
Interventions
Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody
Drug
Lead sponsor
Duke University
Other
Eligibility
6 Weeks to 30 Weeks
Enrollment
524 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
6
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 15, 2026, 4:22 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

NCT06686654
View directory record Official record
Conditions
Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Interventions
Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
1,530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 15, 2026, 4:22 PM EDT
Terminated Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

NCT02593851
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections, Virus Diseases
Interventions
JNJ-53718678, Placebo
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
1 Month to 24 Months
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 15, 2026, 4:22 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

NCT07768345
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSVpreF Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Decatur, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

NCT05101486
View directory record Official record
Conditions
Respiratory Syncytial Virus Prevention
Interventions
Ad26.RSV.PreF-based Vaccine
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years to 75 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Athens, Alabama • Vestavia Hills, Alabama • Phoenix, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

NCT04498741
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

NCT05169905
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT vaccine, dTpa vaccine
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 49 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Beaumont, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

NCT00686075
View directory record Official record
Conditions
Healthy
Interventions
MEDI-534, Cohort 1, Placebo, Cohort 1, MEDI-534, Cohort 2, Placebo, Cohort 2, MEDI-534, Cohort 3, Placebo, Cohort 3, MEDI-534, Cohort 4, Placebo, Cohort 4, MEDI-534, Cohort 5, Placebo, Cohort 5
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Months to 23 Months
Enrollment
1,338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
51
States / cities
Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2014 · Synced Oct 15, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT03387137
View directory record Official record
Conditions
RSV Infection
Interventions
RSV 6120/∆NS2/1030s, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 60 Months
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 15, 2026, 4:22 PM EDT